{"nctId":"NCT01573910","briefTitle":"An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients","startDateStruct":{"date":"2012-05"},"conditions":["Bacterial Conjunctivitis"],"count":985,"armGroups":[{"label":"Moxifloxacin","type":"EXPERIMENTAL","interventionNames":["Drug: Moxifloxacin ophthalmic solution, 0.5%"]},{"label":"Ofloxacin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ofloxacin ophthalmic solution, 0.3%"]}],"interventions":[{"name":"Moxifloxacin ophthalmic solution, 0.5%","otherNames":["VIGAMOX®"]},{"name":"Ofloxacin ophthalmic solution, 0.3%","otherNames":["Tarivid® Eye Drops"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Chinese.\n* Diagnosis of bacterial conjunctivitis based on clinical observation.\n* Understand and sign the approved informed consent. Legally authorized representative can provide informed consent for patients less than 18 years old and/or incapable of understanding the informed consent.\n* Willing to complete all required study procedures and visits.\n* Other protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Women who are pregnant, lactating, or planning a pregnancy.\n* Only 1 sighted eye or vision not correctable to 0.6 logMAR or better in either eye.\n* Planned contact lens wear during the course of the study.\n* Signs and symptoms of bacterial conjunctivitis for longer than 4 days prior to Screening (Day 1).\n* Suspected fungal, viral, or Acanthamoeba infection.\n* Any systemic or ocular disease or disorder, complicating factor or structural abnormality that would negatively affect the conduct or outcome of the study.\n* History of recent surgery.\n* Presence of concomitant systemic viral infection.\n* Other protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Cure Rate","description":"Ocular signs of bacterial conjunctivitis (bulbar conjunctival injection and conjunctival discharge/exudates) were rated by the investigator on a 4-point scale, with 0=normal/absent; 1=mild; 2=moderate, and 3=severe. Clinical cure rate is presented as the percentage of participants for which the sum of the numerical scores for the 2 cardinal ocular signs of bacterial conjunctivitis was 0 at Day 9 TOC/Exit Visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":null},{"groupId":"OG001","value":"81.4","spread":null}]}]}]},{"type":"PRIMARY","title":"Microbiological Success Rate","description":"Microbiological specimen(s) from the affected eye(s) were collected according to a protocol-defined process. Microbiological success rate is presented as the percentage of participants for which the pre-therapy pathogens at Visit 1 (Day 1) were eradicated at Day 9 TOC/Exit Visit.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.3","spread":null},{"groupId":"OG001","value":"94.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":489},"commonTop":[]}}}